ALTY-0501

· Alacrity Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALTY-0501, covering 2007-10-02 to 2007-10-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period [Phase 2]